UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fesoterodine (Toviaz) for Overactive Bladder

Obstetrics and gynecology (New York. 1953), 2009-09, Vol.114 (3), p.682-683

2009

Volltextzugriff (PDF)

Effects of β3 Agonists and Anticholinergic Drugs on Defecation in Patients With Overactive Bladder

In vivo (Athens), 2022-07, Vol.36 (4), p.1847-1853

2022

Volltextzugriff (PDF)

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

European urology, 2008-09, Vol.54 (3), p.543-562

2008

Volltextzugriff (PDF)

The Utility of Modeling and Simulation in Drug Development and Regulatory Review

Journal of pharmaceutical sciences, 2013-09, Vol.102 (9), p.2912-2923

2013

Volltextzugriff (PDF)

Comparison of static and dynamic mode in the electrochemical oxidation of fesoterodine with the use of experimental design approach

Talanta (Oxford), 2021-05, Vol.226, p.122141-122141, Article 122141

2021

Volltextzugriff (PDF)

Crystallization of fesoterodine fumarate active pharmaceutical ingredient: Modelling of thermodynamic equilibrium, nucleation, growth, agglomeration and dissolution kinetics and temperature cycling

Chemical engineering science, 2019-06, Vol.201, p.97-111

2019

Volltextzugriff (PDF)

Evaluation and Treatment of Overactive Bladder in Women

Mayo Clinic proceedings, 2020-02, Vol.95 (2), p.370-377

2020

Volltextzugriff (PDF)

Fesoterodine: Pharmacological properties and clinical implications

European journal of pharmacology, 2018-08, Vol.833, p.155-157

2018

Volltextzugriff (PDF)

Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children

Expert opinion on pharmacotherapy, 2022-05, Vol.23 (8), p.991-1002

2022

Volltextzugriff (PDF)

Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility

Respirology (Carlton, Vic.), 2022-11, Vol.27 (11), p.975-982

2022

Volltextzugriff (PDF)

Validated stability-indicating RP-HPLC assay method for fesoterodine fumarate in pharmaceutical products

Acta Poloniae pharmaceutica, 2023-01, Vol.80 (1), p.33-43

2023

Volltextzugriff (PDF)

Effect of Fesoterodine in Vulnerable Elderly Subjects with Urgency Incontinence: A Double-Blind, Placebo Controlled Trial

The Journal of urology, 2014-02, Vol.191 (2), p.395-404

2014

Volltextzugriff (PDF)

A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder–wet Patients over the Age of 75 Years with Mild Cognitive Impairment

European urology focus, 2024-03, Vol.10 (2), p.325-331

2024

Volltextzugriff (PDF)

On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics

International Urogynecology Journal, 2022-08, Vol.33 (8), p.2127-2132

2022

Volltextzugriff (PDF)

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder

European urology, 2008-10, Vol.54 (4), p.740-764

2008

Volltextzugriff (PDF)

Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate

Drug design, development and therapy, 2019-07, Vol.13, p.2459-2474

2019

Volltextzugriff (PDF)

Detection of antimuscarinic agents tolterodine and fesoterodine and their metabolite 5-hydroxymethyl tolterodine by ion transfer voltammetry at a polarized room-temperature ionic liquid membrane

Electrochimica acta, 2019-05, Vol.304, p.54-61

2019

Volltextzugriff (PDF)

Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder

Drug metabolism and pharmacokinetics, 2024-06, Vol.56, p.100998, Article 100998

2024

Volltextzugriff (PDF)

Flexible-Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled Study of Fesoterodine in an Aging Population Trial

Journal of the American Geriatrics Society (JAGS), 2013-02, Vol.61 (2), p.185-193

2013

Volltextzugriff (PDF)

Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study

Neurourology and urodynamics, 2021-11, Vol.40 (8), p.2026-2033

2021

Volltextzugriff (PDF)

An Investigational Study on the Role of CYP2D6, CYP3A4 and UGTs Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers

Pharmaceuticals (Basel, Switzerland), 2024-09, Vol.17 (9), p.1236

2024

Volltextzugriff (PDF)

A comprehensive non‐clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder

British journal of clinical pharmacology, 2011-08, Vol.72 (2), p.235-246

2011

Volltextzugriff (PDF)

Inhibition of voltage-dependent K + channels by antimuscarinic drug fesoterodine in coronary arterial smooth muscle cells

The Korean Journal of Physiology & Pharmacology, 2022, 26(5), , pp.397-404

2022

Volltextzugriff (PDF)

Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder

Clinical interventions in aging, 2020-01, Vol.15, p.1493-1503

2020

Volltextzugriff (PDF)

Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole

Drug metabolism and pharmacokinetics, 2018-02, Vol.33 (1), p.90-95

2018

Volltextzugriff (PDF)

1 – 25 von 164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Fesoterodine
(150)
Science & Technology
(129)
Life Sciences & Biomedicine
(116)
Humans
(83)
Overactive Bladder
(74)
Urinary Bladder, Overactive - Drug Therapy
(63)
Female
(58)
Male
(54)
Urology & Nephrology
(50)
Aged
(44)
Middle Aged
(43)
Muscarinic Antagonists - Therapeutic Use
(41)
Benzhydryl Compounds - Therapeutic Use
(39)
Pharmacology & Pharmacy
(39)
Urinary Incontinence
(38)
Urology
(38)
Adult
(35)
Treatment Outcome
(29)
Bladder
(28)
Biological And Medical Sciences
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fesoterodine (Toviaz) for Overactive Bladder

Effects of β3 Agonists and Anticholinergic Drugs on Defecation in Patients With Overactive Bladder

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

The Utility of Modeling and Simulation in Drug Development and Regulatory Review

Comparison of static and dynamic mode in the electrochemical oxidation of fesoterodine with the use of experimental design approach

Crystallization of fesoterodine fumarate active pharmaceutical ingredient: Modelling of thermodynamic equilibrium, nucleation, growth, agglomeration and dissolution kinetics and temperature cycling

Evaluation and Treatment of Overactive Bladder in Women

Fesoterodine: Pharmacological properties and clinical implications

Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children

Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility

Validated stability-indicating RP-HPLC assay method for fesoterodine fumarate in pharmaceutical products

Effect of Fesoterodine in Vulnerable Elderly Subjects with Urgency Incontinence: A Double-Blind, Placebo Controlled Trial

A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder–wet Patients over the Age of 75 Years with Mild Cognitive Impairment

On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder

Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate

Detection of antimuscarinic agents tolterodine and fesoterodine and their metabolite 5-hydroxymethyl tolterodine by ion transfer voltammetry at a polarized room-temperature ionic liquid membrane

Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder

Flexible-Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled Study of Fesoterodine in an Aging Population Trial

Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study

An Investigational Study on the Role of CYP2D6, CYP3A4 and UGTs Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers

A comprehensive non‐clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder

Inhibition of voltage-dependent K + channels by antimuscarinic drug fesoterodine in coronary arterial smooth muscle cells

Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder

Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole

Suchergebnisse filtern